Welcome to our dedicated page for CDT Equity Inc, SEC filings (Ticker: CDTTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CDT Equity Inc,'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CDT Equity Inc,'s regulatory disclosures and financial reporting.
CDT Equity Inc. investors Prospect Capital Securities, Prospect Finance and Mark Taylor filed Amendment No. 1 to their Schedule 13D to report that they no longer beneficially own CDT Equity common stock. The filing describes open‑market sales on June 18, 2026 that reduced their holdings to zero, representing approximately 0.0% of the 4,722,458 shares outstanding as of June 22, 2026. The amendment is characterized as an exit filing and notes a previously effected 1‑for‑25 reverse stock split on March 26, 2026, which is reflected in the share figures reported.
CDT Equity Inc. investors Prospect Capital Securities, Prospect Finance and Mark Taylor filed Amendment No. 1 to their Schedule 13D to report that they no longer beneficially own CDT Equity common stock. The filing describes open‑market sales on June 18, 2026 that reduced their holdings to zero, representing approximately 0.0% of the 4,722,458 shares outstanding as of June 22, 2026. The amendment is characterized as an exit filing and notes a previously effected 1‑for‑25 reverse stock split on March 26, 2026, which is reflected in the share figures reported.
CDT Equity Inc. disclosed that entities associated with major shareholder Mark Taylor sold a combined 2,068,000 shares of Common Stock in open-market transactions on June 18, 2026. Prospect Capital Securities Limited sold 1,469,711 shares at prices including $1.44 and $0.7052 per share, while Prospect Finance Limited sold 598,289 shares at prices including $1.25–$1.67 and $0.751 per share. Following these sales, each entity reported holding zero CDT Equity common shares. The reported share amounts give effect to a 1-for-25 reverse split effective as of March 26, 2026.
CDT Equity Inc. disclosed that entities associated with major shareholder Mark Taylor sold a combined 2,068,000 shares of Common Stock in open-market transactions on June 18, 2026. Prospect Capital Securities Limited sold 1,469,711 shares at prices including $1.44 and $0.7052 per share, while Prospect Finance Limited sold 598,289 shares at prices including $1.25–$1.67 and $0.751 per share. Following these sales, each entity reported holding zero CDT Equity common shares. The reported share amounts give effect to a 1-for-25 reverse split effective as of March 26, 2026.
CDT Equity Inc. has restructured its financing, eliminating over $6.3 million of legacy obligations while entering a new secured convertible loan facility. The company repaid a $5,737,500 A.G.P. convertible note and will repay $555,555.56 to Ascent Partners, leaving a single senior secured convertible note with J.J. Astor & Co.
Under the new Loan Agreement, CDT will receive up to $1,460,000 against a senior secured convertible promissory note with a principal amount of $1,971,000, repayable in twenty-four weekly installments of $82,125. The note can be converted into common stock after six months at a variable price tied to the stock’s volume-weighted average price and subject to Nasdaq Rule 5635(d) and ownership caps of 4.99% or, at the lender’s election, 9.99%.
CDT also issued warrants to purchase 912,500 shares at $0.72 per share, with all conversion and warrant issuance above 19.99% of current outstanding shares requiring stockholder approval. The note is interest-free unless a default occurs, in which case the amount due increases to 120% of the outstanding balance and accrues interest at 19% per annum, compounded daily.
CDT Equity Inc. has restructured its financing, eliminating over $6.3 million of legacy obligations while entering a new secured convertible loan facility. The company repaid a $5,737,500 A.G.P. convertible note and will repay $555,555.56 to Ascent Partners, leaving a single senior secured convertible note with J.J. Astor & Co.
Under the new Loan Agreement, CDT will receive up to $1,460,000 against a senior secured convertible promissory note with a principal amount of $1,971,000, repayable in twenty-four weekly installments of $82,125. The note can be converted into common stock after six months at a variable price tied to the stock’s volume-weighted average price and subject to Nasdaq Rule 5635(d) and ownership caps of 4.99% or, at the lender’s election, 9.99%.
CDT also issued warrants to purchase 912,500 shares at $0.72 per share, with all conversion and warrant issuance above 19.99% of current outstanding shares requiring stockholder approval. The note is interest-free unless a default occurs, in which case the amount due increases to 120% of the outstanding balance and accrues interest at 19% per annum, compounded daily.
CDT Equity Inc. Schedule 13G reports a group of affiliated entities and individuals collectively associated with Ascent Partners Fund LLC that hold or have rights to 543,645 shares of Common Stock, representing 9.9% of the class based on 4,858,350 shares outstanding as reported in the Prospectus. The shares comprise the maximum issuable under a Directed Stock Purchase Agreement dated January 16, 2026 (the "ELOC Agreement") and are subject to a 9.99% beneficial ownership limit (the "Blocker"). As of June 5, 2026, Ascent holds no shares directly, there are 543,645 shares issuable under the ELOC Agreement (the Blocker maximum), and an internal reorganization on June 1, 2026 moved management such that Dominion Capital Holdings LLC ceased to hold voting or dispositive power and Eagle Claw became a >5% beneficial owner.
CDT Equity Inc. Schedule 13G reports a group of affiliated entities and individuals collectively associated with Ascent Partners Fund LLC that hold or have rights to 543,645 shares of Common Stock, representing 9.9% of the class based on 4,858,350 shares outstanding as reported in the Prospectus. The shares comprise the maximum issuable under a Directed Stock Purchase Agreement dated January 16, 2026 (the "ELOC Agreement") and are subject to a 9.99% beneficial ownership limit (the "Blocker"). As of June 5, 2026, Ascent holds no shares directly, there are 543,645 shares issuable under the ELOC Agreement (the Blocker maximum), and an internal reorganization on June 1, 2026 moved management such that Dominion Capital Holdings LLC ceased to hold voting or dispositive power and Eagle Claw became a >5% beneficial owner.
CDT Equity Inc. reported receiving a Nasdaq deficiency notice because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time, as required by Nasdaq Listing Rule 5250(c)(1) governing periodic filings. The notice does not immediately affect trading or the listing of its common stock or warrants on The Nasdaq Capital Market.
Nasdaq has given the company until July 20, 2026 to submit a plan to regain compliance. CDT Equity anticipates filing the delayed Form 10‑Q once its review process is complete, which it expects will restore compliance with the periodic filing requirement.
CDT Equity Inc. reported receiving a Nasdaq deficiency notice because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time, as required by Nasdaq Listing Rule 5250(c)(1) governing periodic filings. The notice does not immediately affect trading or the listing of its common stock or warrants on The Nasdaq Capital Market.
Nasdaq has given the company until July 20, 2026 to submit a plan to regain compliance. CDT Equity anticipates filing the delayed Form 10‑Q once its review process is complete, which it expects will restore compliance with the periodic filing requirement.
CDT Equity Inc. Schedule 13G: a Nirland/Stockton/Rowland/Dovet group reports shared beneficial ownership of 75,315 shares of Common Stock, equal to 1.6% of the class. The group states it exceeded 5% on 02/19/2026, which triggered the reporting obligation; ownership has since decreased below 5% as of this filing. The filing lists shared voting and dispositive power for 75,315 shares and includes a Joint Filing Agreement dated 05/20/2026.
CDT Equity Inc. Schedule 13G: a Nirland/Stockton/Rowland/Dovet group reports shared beneficial ownership of 75,315 shares of Common Stock, equal to 1.6% of the class. The group states it exceeded 5% on 02/19/2026, which triggered the reporting obligation; ownership has since decreased below 5% as of this filing. The filing lists shared voting and dispositive power for 75,315 shares and includes a Joint Filing Agreement dated 05/20/2026.
CDT Equity Inc. submitted a Form 12b-25 notification that its Quarterly Report on Form 10-Q for the period ended March 31, 2026 could not be filed on time. The company says it could not, without unreasonable effort or expense, compile all financial statement information and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.
The filing discloses the company anticipates stockholders' equity will increase from a deficit as of December 31, 2025 and that the company will report a greater loss for the quarter versus the year‑ago period; amounts remain under review. The notification is signed by CEO Andrew Regan on May 15, 2026.
CDT Equity Inc. submitted a Form 12b-25 notification that its Quarterly Report on Form 10-Q for the period ended March 31, 2026 could not be filed on time. The company says it could not, without unreasonable effort or expense, compile all financial statement information and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.
The filing discloses the company anticipates stockholders' equity will increase from a deficit as of December 31, 2025 and that the company will report a greater loss for the quarter versus the year‑ago period; amounts remain under review. The notification is signed by CEO Andrew Regan on May 15, 2026.
CDT Equity Inc. entered into amendments to its equity line of credit and a related senior secured convertible note. The company and its institutional investor set the gross purchase price for each regular ELOC closing, without purchaser consent, at $510,000. The note amendment allows the company to retain 90% of proceeds from any debt or equity financing, including the ELOC, while 10% must be applied to amounts due under the note. Both amendments are effective through May 31, 2026 and then cease to modify the original agreements.
CDT Equity Inc. entered into amendments to its equity line of credit and a related senior secured convertible note. The company and its institutional investor set the gross purchase price for each regular ELOC closing, without purchaser consent, at $510,000. The note amendment allows the company to retain 90% of proceeds from any debt or equity financing, including the ELOC, while 10% must be applied to amounts due under the note. Both amendments are effective through May 31, 2026 and then cease to modify the original agreements.
Corvus Capital Ltd. and Andrew Regan filed Amendment No. 5 to their Schedule 13D on CDT Equity Inc., updating their ownership following recent share issuances and purchases. Corvus now beneficially owns 257,166 common shares, representing about 5.3% of the outstanding stock, while Dr. Regan beneficially owns 262,766 shares, or about 5.4%.
On March 24, 2026, CDT Equity issued Corvus 147,401 shares through a cashless exercise of all its Pre-Funded Warrants, after a 1-for-25 reverse stock split of its common stock. On May 13, 2026, Corvus purchased 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, funded with cash on hand. The filing states the CDT shares were acquired for investment purposes.
Corvus Capital Ltd. and Andrew Regan filed Amendment No. 5 to their Schedule 13D on CDT Equity Inc., updating their ownership following recent share issuances and purchases. Corvus now beneficially owns 257,166 common shares, representing about 5.3% of the outstanding stock, while Dr. Regan beneficially owns 262,766 shares, or about 5.4%.
On March 24, 2026, CDT Equity issued Corvus 147,401 shares through a cashless exercise of all its Pre-Funded Warrants, after a 1-for-25 reverse stock split of its common stock. On May 13, 2026, Corvus purchased 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, funded with cash on hand. The filing states the CDT shares were acquired for investment purposes.
CDT Equity Inc. director and CEO Dr. Regan reported indirect purchases and conversions through affiliated entities. On March 24, 2026, Corvus Capital Limited, which he controls, exercised all its pre-funded warrants via cashless exercise into 147,401 shares of Common Stock, eliminating the warrant position. On May 13, 2026, Corvus bought an additional 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, bringing Corvus’s reported Common Stock holdings to 256,393 shares. Separate indirect holdings via Manoira Corporation total 773 shares, and Dr. Regan also holds 5,600 shares directly. All share amounts reflect a 1‑for‑25 reverse stock split effected on March 26, 2026.
CDT Equity Inc. director and CEO Dr. Regan reported indirect purchases and conversions through affiliated entities. On March 24, 2026, Corvus Capital Limited, which he controls, exercised all its pre-funded warrants via cashless exercise into 147,401 shares of Common Stock, eliminating the warrant position. On May 13, 2026, Corvus bought an additional 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, bringing Corvus’s reported Common Stock holdings to 256,393 shares. Separate indirect holdings via Manoira Corporation total 773 shares, and Dr. Regan also holds 5,600 shares directly. All share amounts reflect a 1‑for‑25 reverse stock split effected on March 26, 2026.